

IN THE CLAIMS

Please cancel claims 1-26, 31-35, 38-60, and 63 without prejudice to refiling these as part of a divisional patent application.

Please amend the following claims:

3 ~~36~~ (amended). An isolated nucleic acid comprising any 15 consecutive nucleotides of SEQ ID NO:1 or its complement wherein SEQ ID NO:1 comprises one or more mutations selected from the group consisting of: an A at base 664, an A at base 1102, a G at base 1106, a C at base 1116, a C at base 1220, a T at base 1258, a deletion of bases 662-664, a C at base 694, an A at base 727, an A at base 731, an A at base 922, a T at base 979, an A at base 1078, a T at base 1097, an A at base 1184, a T at base 1184 [or] and an A at base 1196, and wherein said isolated nucleic acid comprises one or more of said mutations.--

4/ ~~37~~ ⁴ (amended). An isolated nucleic acid comprising any 12 consecutive nucleotides of SEQ ID NO:1 or its complement wherein SEQ ID NO:1 comprises one or more mutations selected from the group consisting of: an A at base 664, an A at base 1102, a G at base 1106, a C at base 1116, a C at base 1220, a T at base 1258, a deletion of bases 662-664, a C at base 694, an A at base 727, an A at base 731, an A at base 922, a T at base 979, an A at base 1078, a T at base 1097, an A at base 1184, a T at base 1184 [or] and an A at base 1196, and wherein said isolated nucleic acid comprises one or more of said mutations.--

but 4/62 ~~61~~ (amended). An isolated nucleic acid comprising any 15 consecutive nucleotides of [the nucleic acid of claim 59] a nucleic acid encoding a *Xenopus* KVLQT1 polypeptide having the amino acid sequence set forth in SEQ ID NO:113 or its complement.--

~~62~~ (amended). An isolated nucleic acid comprising any 12 consecutive nucleotides of [the nucleic acid of claim 59] a nucleic acid encoding a *Xenopus* KVLQT1 polypeptide having the amino acid sequence set forth in SEQ ID NO:113 or its complement.--

Please add the following new claims:

95 ~~64~~. An isolated nucleic acid comprising any 15 consecutive nucleotides of SEQ ID NO:115 or its complement.--

~~65~~⁸. An isolated nucleic acid comprising any 12 consecutive nucleotides of SEQ ID NO:115 or its complement.--

~~66~~⁹. An isolated nucleic acid comprising any 15 consecutive nucleotides of SEQ ID NO:115 or its complement wherein SEQ ID NO:115 comprises one or more mutations selected from the group consisting of: an A at base 304, an A at base 742, a G at base 746, a C at base 756, a C at base 860, a T at base 898, a deletion of bases 302-304, a C at base 334, an A at base 367, an A at base 371, an A at base 562, a T at base 619, an A at base 718, a T at base 737, an A at base 824, a T at base 824 and an A at base 836, and wherein said isolated nucleic acid comprises one or more of said mutations.--

~~67~~¹⁰. An isolated nucleic acid comprising any 12 consecutive nucleotides of SEQ ID NO:115 or its complement wherein SEQ ID NO:115 comprises one or more mutations selected from the group consisting of: an A at base 304, an A at base 742, a G at base 746, a C at base 756, a C at base 860, a T at base 898, a deletion of bases 302-304, a C at base 334, an A at base 367, an A at base 371, an A at base 562, a T at base 619, an A at base 718, a T at base 737, an A at base 824, a T at base 824 and an A at base 836, and wherein said isolated nucleic acid comprises one or more of said mutations.--

IN THE SEQUENCE LISTING

Please replace the Sequence Listing with the new Sequence Listing attached hereto. The replacement Sequence Listing is identical with a replacement Sequence Listing which was submitted for parent application Serial No. 09/135,010 on 30 May 2000.

139

A